LewisDSchnollSH.Commentary on the 40th anniversary of AMERSA: AMERSA at 40: how it all began and how it survived. Subst Abuse. 2018;39(2):134-138. doi:10.1080/08897077.2018.1495892
2.
SametJHGalanterMBriddenCLewisDC.Association for medical education and research in substance abuse. Addiction. 2006;101(1-2):10-15. doi:10.1111/j.1360-0443.2005.01228.x
3.
National Drug Control Strategy. The White House, Executive Office of the President. Office of National Drug Control Policy; 2022.
4.
SpencerMMiniñoAWarnerM.Drug Overdose Deaths in the United States, 2001–2021. National Center for Health Statistics (U.S.); 2022. doi:10.15620/cdc:122556
5.
Rising Numbers of Deaths Involving Fentanyl and Fentanyl Analogs, Including Carfentanil, and Increased Usage and Mixing With Non-opioids. Centers for Disease Control Health Alert Network; 2018.
6.
O’DonnellJGladdenRMMattsonCLKariisaM.Notes from the field: overdose deaths with carfentanil and other fentanyl analogs detected - 10 states, July 2016-June 2017. MMWR Morb Mortal Wkly Rep. 2018;67(27):767-768. doi:10.15585/mmwr.mm6727a4
7.
BittingJO’DonnellJMattsonCL.Notes from the Field: overdose deaths involving para -fluorofentanyl—United States, July 2020–June 2021. MMWR Morb Mortal Wkly Rep. 2022;71(39):1239-1240. doi:10.15585/mmwr.mm7139a3
8.
RaufUAliMDeheleIPaudyalVElnaemMHCheemaE.Causes, nature and toxicology of fentanyl-analogues associated fatalities: a systematic review of case reports and case series. J Pain Res. 2021;14:2601-2614. doi:10.2147/JPR.S312227
9.
WhiteAMCastleIPPowellPAHingsonRWKoobGF.Alcohol-related deaths during the COVID-19 pandemic. JAMA. 2022;327(17):1704-1706. doi:10.1001/jama.2022.4308
10.
Center for Behavioral Health Statistics and Quality. Racial/Ethnic Differences in Substance Use, Substance Use Disorders, and Substance Use Treatment Utilization Among People Aged 12 Or Older (2015-2019). Substance Abuse and Mental Health Services Administration; 2021. Accessed April 19, 2023. https://www.samhsa.gov/data/
11.
MennisJStahlerGJEl MagdSABaronDA.How long does it take to complete outpatient substance use disorder treatment? Disparities among blacks, Hispanics, and Whites in the US. Addict Behav. 2019;93:158-165. doi:10.1016/j.addbeh.2019.01.041
12.
JordanAQuainooSNichCBabuscioTAFunaroMCCarrollKM.Racial and ethnic differences in alcohol, cannabis, and illicit substance use treatment: a systematic review and narrative synthesis of studies done in the USA. Lancet Psychiatry. 2022;9(8):660-675. doi:10.1016/S2215-0366(22)00160-2
13.
BairdAChengYXiaY.Use of machine learning to examine disparities in completion of substance use disorder treatment. PLoS One. 2022;17(9):e0275054. doi:10.1371/journal.pone.0275054
14.
HagleHNMartinMWinogradR, et al. Dismantling racism against black, indigenous, and people of color across the substance use continuum: a position statement of the association for multidisciplinary education and research in substance use and addiction. Subst Abuse. 2021;42(1-2):5-12. doi:10.1080/08897077.2020.1867288
15.
Providers Clinical Support System. Accessed April 19, 2023. https://pcssnow.org/
16.
Boston Medical Center. Grayken Center for Addiction Training and Technical Assistance. Accessed April 19, 2023. https://www.addictiontraining.org/
17.
GordonAJKennyMDunganM, et al. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings. Am J Addict. 2022;31(2):152-158. doi:10.1111/ajad.13260
18.
GordonAJLibertoJGrandaSSalmon-CoxSAndreeTMcNicholasL.Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008;17(6):459-462. doi:10.1080/10550490802408613
LaBelleCTHanSCBergeronASametJH.Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in community health centers. J Subst Abuse Treat. 2016;60:6-13. doi:10.1016/j.jsat.2015.06.010
TaylorJLLaksJChristinePJ, et al. Bridge clinic implementation of “72-hour rule” methadone for opioid withdrawal management: impact on opioid treatment program linkage and retention in care. Drug Alcohol Depend. 2022;236:109497. doi:10.1016/j.drugalcdep.2022.109497
31.
LaksJKehoeJFarrellNM, et al. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule. Addict Sci Clin Pract. 2021;16(1-2):73. doi:10.1186/s13722-021-00279-x
32.
SaitzRMayo-SmithMFRobertsMSRedmondHABernardDRCalkinsDR.Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA. 1994;272(7):519-523.
33.
KosteniukBSalvalaggioGWildTCGelbergLHyshkaE.Perceived unmet substance use and mental health care needs of acute care patients who use drugs: a cross-sectional analysis using the behavioral model for vulnerable populations. Drug Alcohol Rev. 2022;41(4):830-840. doi:10.1111/dar.13417
34.
KosteniukBSalvalaggioGMcNeilR, et al. “You don’t have to squirrel away in a staircase”: patient motivations for attending a novel supervised drug consumption service in acute care. Int J Drug Policy. 2021;96:103275. doi:10.1016/j.drugpo.2021.103275
35.
EnglanderHJonesAKrawczykN, et al. A taxonomy of hospital-based addiction care models: a scoping review and key informant interviews. J Gen Intern Med. 2022;37(11):2821-2833. doi:10.1007/s11606-022-07618-x
36.
JainAChristopherPAppelbaumPS.Civil commitment for opioid and other substance use disorders: does it work?Psychiatr Serv. 2018;69(4):374-376. doi:10.1176/appi.ps.201800066
BroyanVRBrarJKAllgaier StudentTAllgaierJT.Long-term buprenorphine treatment for kratom use disorder: a case series. Subst Abuse. 2022;43(1-2):763-766. doi:10.1080/08897077.2021.2010250
39.
GordonAJ.Integrating policy and research into addiction practice, AMERSA abstracts, and an appreciation to our reviewers. Subst Abuse. 2016;37(2):271-275. doi:10.1080/08897077.2016.1170091
40.
GordonAJ.The 40th annual meeting of AMERSA: highlights, abstracts, and awards. Subst Abuse. 2017;38(1-2):1. doi:10.1080/08897077.2017.1281646
41.
GordonAJ.Abstracts presented at the Association for Medical Education and Research in Substance Abuse (AMERSA) 41st Annual Conference, Washington, DC, USA, November 2017. Subst Abuse. 2018;39(1-2):1. doi:10.1080/08897077.2018.1441944
42.
GordonAJ.AMERSA’s 42nd annual meeting: highlights, abstracts and awards, and an appreciation to our peer reviewers. Subst Abuse. 2019;40(1-2):2-3. doi:10.1080/08897077.2019.1613824
43.
Mountain-RaySFinnellDRoyPNorthupRMacLane-BaederD.Confronting COVID, racism, and addiction: the association of multidisciplinary education and research in substance use and addiction (AMERSA). Subst Abuse. 2021;42(1-2):1-4. doi:10.1080/08897077.2020.1866144
44.
Mountain-RaySSimeoneCHadlandSEFinnellDSNorthupRMacLane-BaederD.Challenges and new horizons in substance use and addictions: overview of the 2019 conference of the Association of Multidisciplinary Education and Research in substance use and addiction (AMERSA). Subst Abuse. 2019;40(4):389-391. doi:10.1080/08897077.2019.1695039
45.
OlivaEMBagleySMBottnerRNorthupRMacLane-BaederD.Association of multidisciplinary education and research in substance use and addiction’s (AMERSA) 2021 transforming care through evidence and policy conference: tackling stigma and giving voice to lived experience. Subst Abuse. 2022;43(1-2):1341-1345. doi:10.1080/08897077.2022.2074607
46.
HeimerRBluthenthalRNSingerMKhoshnoodK.Structural impediments to operational syringe-exchange programs. AIDS Public Policy J. 1996;11(4):169-184.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
